Interferon-β 1a and SARS coronavirus replication

被引：142

作者：

Hensley, LE

Fritz, EA

Jahrling, PB

Karp, CL

Huggins, JW

Geisbert, TW

机构：

[1] USA, Med Res Inst Infect Dis, MCMR UIZ, Ft Detrick, MD 21702 USA

[2] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA

来源：

EMERGING INFECTIOUS DISEASES | 2004年 / 10卷 / 02期

关键词：

D O I：

10.3201/eid1002.030482

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon -beta la potently inhibits SARS coronavirus replication in vitro.

引用

页码：317 / 319

页数：3

共 10 条

[1] Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs [J].

Anand, K ;

Ziebuhr, J ;

Wadhwani, P ;

Mesters, JR ;

Hilgenfeld, R .

SCIENCE, 2003, 300 (5626) :1763-1767

[2] A comparison of the biologic activity of two recombinant IFN-β preparations used in the treatment of relapsing-remitting multiple sclerosis [J].

Antonetti, F ;

Finocchiaro, O ;

Mascia, M ;

Terlizzese, MG ;

Jaber, A .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2002, 22 (12) :1181-1184

[3] Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-β1a monkeys [J].

Mager, DE ;

Neuteboom, B ;

Efthymiopoulos, C ;

Munafo, A ;

Jusko, WJ .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (01) :262-270

[4] The genome sequence of the SARS-associated coronavirus [J].

Marra, MA ;

Jones, SJM ;

Astell, CR ;

Holt, RA ;

Brooks-Wilson, A ;

Butterfield, YSN ;

Khattra, J ;

Asano, JK ;

Barber, SA ;

Chan, SY ;

Cloutier, A ;

Coughlin, SM ;

Freeman, D ;

Girn, N ;

Griffith, OL ;

Leach, SR ;

Mayo, M ;

McDonald, H ;

Montgomery, SB ;

Pandoh, PK ;

Petrescu, AS ;

Robertson, AG ;

Schein, JE ;

Siddiqui, A ;

Smailus, DE ;

Stott, JE ;

Yang, GS ;

Plummer, F ;

Andonov, A ;

Artsob, H ;

Bastien, N ;

Bernard, K ;

Booth, TF ;

Bowness, D ;

Czub, M ;

Drebot, M ;

Fernando, L ;

Flick, R ;

Garbutt, M ;

Gray, M ;

Grolla, A ;

Jones, S ;

Feldmann, H ;

Meyers, A ;

Kabani, A ;

Li, Y ;

Normand, S ;

Stroher, U ;

Tipples, GA ;

Tyler, S .

SCIENCE, 2003, 300 (5624) :1399-1404

[5] PROTECTIVE EFFECT OF RECOMBINANT MURINE INTERFERON-BETA AGAINST MOUSE HEPATITIS-VIRUS INFECTION [J].

MINAGAWA, H ;

TAKENAKA, A ;

MOHRI, S ;

MORI, R .

ANTIVIRAL RESEARCH, 1987, 8 (02) :85-95

[6] Randomized, comparative study of interferon β-1a treatment regimens in MS -: The EVIDENCE trial [J].

Panitch, H ;

Goodin, DS ;

Francis, G ;

Chang, P ;

Coyle, PK ;

O'Connor, P ;

Monaghan, E ;

Li, D ;

Weinshenker, B .

NEUROLOGY, 2002, 59 (10) :1496-1506

[7] Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory illness [J].

Pei, JW ;

Sekellick, MJ ;

Marcus, PI ;

Choi, IS ;

Collisson, EW .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (12) :1071-1077

[8] Coronavirus as a possible cause of severe acute respiratory syndrome [J].

Peiris, JSM ;

Lai, ST ;

Poon, LLM ;

Guan, Y ;

Yam, LYC ;

Lim, W ;

Nicholls, J ;

Yee, WKS ;

Yan, WW ;

Cheung, MT ;

Cheng, VCC ;

Chan, KH ;

Tsang, DNC ;

Yung, RWH ;

Ng, TK ;

Yuen, KY .

LANCET, 2003, 361 (9366) :1319-1325

[9] COMPARATIVE SUSCEPTIBILITY OF RESPIRATORY VIRUSES TO RECOMBINANT INTERFERON-ALPHA-2B AND INTERFERON-BETA [J].

SPERBER, SJ ;

HAYDEN, FG .

JOURNAL OF INTERFERON RESEARCH, 1989, 9 (03) :285-293

[10] Down-regulation of Bgp1a viral receptor by interferon-γ is related to the antiviral state and resistance to mouse hepatitis virus 3 infection [J].

Vassao, RC ;

de Franco, MT ;

Hartz, D ;

Modolell, M ;

Sippel, AE ;

Pereira, CA .

VIROLOGY, 2000, 274 (02) :278-283

← 1 →